Skin Aging Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating The Safety And Efficacy Of An Oral Supplement Containing Astaxanthin (2 mg) + Lycopene (1.8 mg) + D-Alpha-Tocopherol (10 IU) For The Treatment Of Skin Aging
Verified date | June 2019 |
Source | United Laboratories |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the clinical efficacy of a combination of Astaxanthin (2 mg), Lycopene (1.8 mg), and d-alpha-Tocopherol (10 IU) in terms of its skin anti-aging properties. Specifically, the investigators aim to determine the increase in hydration levels of the skin, decrease in atypical skin pigmentation, and reduction of signs of photoaging, particularly facial fine lines.
Status | Completed |
Enrollment | 100 |
Est. completion date | February 7, 2019 |
Est. primary completion date | October 10, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 30 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Healthy individuals age 30 to 60 years old - Fitzpatrick Skin Type I-IV - Crow's Feet Wrinkle Scale Class 1-2 - Subjects willing to provide written informed consent Exclusion Criteria: - Use of topical or oral anti-aging drug therapy 1 month prior to the study - History of allergy to cosmetics and anti-aging drugs - History of photosensitivity reactions - Any current or past medical condition, including seizures and stroke - History of pigmentation disorder such as but not limited to vitiligo and leukoderma - Immunocompromised state - Pregnant or lactating (pregnancy kit will be used to check) - Patients who have undergone laser, radiofrequency, peeling, and other procedural therapies for anti-aging in the month prior to the study. - Patients with current inflammatory or infectious skin disease on the face, or history of such in the month prior to the study. - Patients taking OCDs and other photosensitizing drugs (e.g. tetracycline). - Not willing to provide informed consent |
Country | Name | City | State |
---|---|---|---|
Philippines | PDC Building, 1440 Taft Avenue | Manila | Metro Manila |
Lead Sponsor | Collaborator |
---|---|
United Laboratories |
Philippines,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of subjects within each treatment group with a significant decrease in skin wrinkling measured by a validated Crow's Feet Wrinkle scale. | The scale ratings are 0 for no wrinkles, 1 for very fine wrinkles, 2 for fine wrinkles, 3 for moderate wrinkles, and 4 for severe wrinkles. | 12 weeks | |
Secondary | Proportion of subjects within each treatment group with a significant increase in skin hydration measured by a corneometer. | 12 weeks | ||
Secondary | Proportion of subjects within each treatment group with a significant decrease in pigmentation measured by a mexameter. | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04276753 -
A Randomized, Double-blinded, Placebo Controlled, Monocentric Study to Evaluate the Anti-ageing and Skin Brightening Benefit of the Test Product in Healthy Female Subjects
|
N/A | |
Completed |
NCT06125912 -
A Comparative Split-Face Study of the Effects of a Retinol Alternative Cream on Improving Facial Skin Aging
|
N/A | |
Completed |
NCT02580370 -
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines
|
Phase 3 | |
Recruiting |
NCT01583478 -
Comparison of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids
|
Phase 4 | |
Completed |
NCT02003833 -
Poly-L-lactic Acid for Skin Quality
|
Phase 4 | |
Completed |
NCT01447342 -
A Study to Evaluate the Safety and Effectiveness of the Cryo-Touch II Device for the Treatment of Forehead and/or Glabellar Lines
|
Phase 2/Phase 3 | |
Completed |
NCT00974480 -
Comparison of Redermic, Rejuva-A and Combination of Both Redermic and Rejuva-A in Subjects With Signs of Aging
|
N/A | |
Completed |
NCT00986570 -
Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face
|
Phase 3 | |
Completed |
NCT00272610 -
Topical Vitamin A Versus Vehicle Cream in the Treatment of Aged Skin
|
Phase 2 | |
Recruiting |
NCT03730649 -
Effect of Topical Sulforaphane on Skin Aging and With Ultraviolet and Visible Light Exposure
|
Early Phase 1 | |
Completed |
NCT03312543 -
Evaluation of the Efficacy and Tolerance of a Light Therapy Mask on Mild to Moderate Brown Spots and Moderate to Severe Facial Wrinkles
|
N/A | |
Active, not recruiting |
NCT05349799 -
TEOSYAL RHA® 1 for Neck Lines, Perioral Lines and Smiling Lines
|
N/A | |
Completed |
NCT03677258 -
Effectiveness and Safety of Collagen Complex COLLOST in Anti-age Therapy
|
N/A | |
Withdrawn |
NCT05854628 -
The Role of Red Flavonoid in Photoaging
|
N/A | |
Completed |
NCT01981980 -
Comparison of the Effects of Carboxytherapy and Radiofrequency on Skin Rejuvenation
|
N/A | |
Not yet recruiting |
NCT00767156 -
Effects of Oral and Topical Sea Buckthorn Oil Treatments on Skin Aging
|
N/A | |
Recruiting |
NCT05813054 -
Clinical Study to Evaluate the Anti-aging Efficacy of Dermial®
|
N/A | |
Not yet recruiting |
NCT04485091 -
TCA Peel and Photobiomodulation for Hand Rejuvenation
|
Phase 2 | |
Completed |
NCT05457491 -
Novel Antiaging Regenerative Skin Care Regimen Containing Human Platelet Extract (HPE)
|
Phase 1 | |
Completed |
NCT01237977 -
Efficacy and Safety Study of Botulinum Toxin Type A to Treat Glabellar Lines
|
Phase 3 |